ACM
CSTL icon

Aster Capital Management’s Castle Biosciences CSTL Stock Holding History

Aster Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-151
Closed -$5.87K – 943
2025
Q4 		$5.87K Buy
+151
New +$4.87K ﹤0.01% 846
2025
Q1 		– Sell
-9
Closed -$240 – 1328
2024
Q4 		$240 Sell
9
-106
-92% -$3.23K ﹤0.01% 1052
2024
Q3 		$3.28K Buy
+115
New +$2.93K ﹤0.01% 941

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aster Capital Management's CSTL Position: Q1 2026 in Review

Aster Capital Management sold out of Castle Biosciences (CSTL) in Q1 2026, closing a stake of 151 shares — an estimated $5.87K sold.

Aster Capital Management first reported a position in CSTL in Q3 2024 and held it in 3 quarters. The position peaked at $5.87K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Aster Capital Management reported no remaining Castle Biosciences position as of Q1 2026 after selling out during the quarter.
  • Aster Capital Management sold 151 Castle Biosciences shares in Q1 2026, an estimated $5.87K.
  • Aster Capital Management first reported a position in Castle Biosciences in Q3 2024 and held it in 3 quarters.
  • Aster Capital Management's Castle Biosciences position peaked at $5.87K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.